Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results from the phase IIIb single-arm PRECONNECT study by duration of therapy

PRECONNECT was an international, phase IIIb trial evaluating the safety and efficacy of trifluridine/tipiracil (FTD/TPI) for metastatic colorectal cancer (mCRC). Patients with mCRC received FTD/TPI 35mg/m2 twice-daily on days 1–5 and 8–12 of each 28-day cycle for third- or later-line treatment.